title: Pharmacokinetics of salicylate ester prodrugs of cyclic HPMPC in dogs.
abstract: A series of aryl ester prodrugs of cyclic HPMPC have been synthesized and their physicochemical properties, pharmacokinetics and metabolism have been evaluated. Chemical stability was dependent on the orientation of the exo-cyclic ligand; the equatorial isomers were 5.4 to 9.4 fold more reactive than the axial isomers. The oral bioavailability of cyclic HPMPC from the aryl ester prodrugs ranged from 11.2% for o-pentylphenyl cyclic HPMPC to 46.3% for butylsalicylyl cyclic HPMPC. Cyclic HPMPC was the major metabolite observed for all the salicylyl ester prodrugs. Cidofovir accounted for 2 to 12% of the total plasma AUC for butyl-, cyclohexyl- and phenethyl-salicylyl esters of cyclic HPMPC. Intact prodrug or the corresponding monosalicylyl esters of cidofovir each accounted for less than 10% of the total AUC for salicylyl ester prodrugs.
authors.affiliation: Gilead Sciences Inc., 335 Lakeside Drive, Foster City, California 94404, USA.
authors.forename: R
authors.initials: R
authors.lastname: Oliyai
authors.forename: M N
authors.initials: MN
authors.lastname: Arimilli
authors.forename: R J
authors.initials: RJ
authors.lastname: Jones
authors.forename: W A
authors.initials: WA
authors.lastname: Lee
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000998:Antiviral Agents / Q000493:pharmacokinetics*; D001682:Biological Availability; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D004285:Dogs; D007408:Intestinal Absorption; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000493:pharmacokinetics*; D011355:Prodrugs / Q000493:pharmacokinetics*; D012459:Salicylates / Q000493:pharmacokinetics*
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D011355:Prodrugs; D012459:Salicylates; D003596:Cytosine; D000077404:Cidofovir